Mologen AG Insolvency Proceedings Opened
First Feedback from Investor Process / Talks With Potential Purchasers for Berlin Biotech Company Continue
BERLIN, 3 FEBRUARY 2020. Charlottenburg District Court opened insolvency proceedings for the Mologen AG based in Berlin. First investors expressed their interest in purchasing the research results from the internationally operating biopharmaceutical company which develops innovative medicines against cancer and infections. Insolvency Administrator Christian Köhler-Ma is continuing talks with potential purchasers.
The company – listed on the Frankfurt Stock Exchange in the regulated market – filed for insolvency on 4 December 2019. Mologen had previously encountered financing issues because a clinical study on a newly developed product failed to yield satisfying results. The company, which was founded in 1998, predominantly develops DNA medicines in order to activate the endogenous immune system in the battle against cancer and infection diseases. Innovative medicines are designed, for instance, to enable the immune system to recognize and destroy cancer cells.
“The talks with potential purchasers of Mologen are encouraging. This is also confirmed by first feedback from the investor process we initiated for an acquisition of research results, brands and patents”, stated Insolvency Administrator Christian Köhler-Ma of the office GT Restructuring.
Christian Köhler-Ma, Insolvency Administrator and Lawyer, GT Restructuring, Potsdamer Platz 1, 10785 Berlin, phone +49 30-700 171 511, email: email@example.com, www.gtrestructuring.com, www.mologen.com
Dr. Jochen Mignat, Dr. Mignat PR, Am Hexenpfad 11, 63450 Hanau, phone +49 6181-507 91-0, firstname.lastname@example.org